ストックスクリーナーアプリを入手
1.25
0.79%
-0.01
前日終値:
$1.26
開ける：
$1.28
24時間の取引高:
161.08K
Relative Volume:
1.10
時価総額：
$52.32M
収益：
$9.16M
当期純損益:
$-68.17M
株価収益率:
-0.7669
EPS:
-1.63
ネットキャッシュフロー:
$-80.16M
1週間 パフォーマンス:
-9.42%
1か月 パフォーマンス:
-8.76%
6か月 パフォーマンス:
-16.67%
1年 パフォーマンス:
-25.15%
1日の値動き範囲:
$1.24
$1.2893
1週間の範囲:
$1.24
$1.47
52週間の値動き範囲:
$0.9707
$1.94
Ikena Oncology Inc Stock (IKNA) Company Profile
IKNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.2491 | 67.08M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.86 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.72 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.56 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.62 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.63 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-09-22 | 開始されました | Wedbush | Outperform |
| 2023-05-04 | 再開されました | H.C. Wainwright | Buy |
| 2021-12-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-20 | 開始されました | Credit Suisse | Outperform |
| 2021-04-20 | 開始されました | Jefferies | Buy |
| 2021-04-20 | 開始されました | William Blair | Outperform |
すべてを表示
Ikena Oncology Inc (IKNA) 最新ニュース
Ikena Oncology Inc. Stock Analysis and ForecastExceptional profit potential - Jammu Links News
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting By Investing.com - Investing.com South Africa
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting - Investing.com
Ikena Oncology Updates Employment Terms Amid Merger Plans - TipRanks
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewswire
How Ikena Oncology Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Ikena Oncology Approves Merger and Reverse Stock Split - TipRanks
Ikena Oncology announces stockholder approval of merger with Inmagene Biopharmaceuticals - MarketScreener
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger - TipRanks
Ikena shareholders approve merger with Inmagene, reverse stock split By Investing.com - Investing.com South Africa
Ikena Oncology Approves Merger with Inmagene Biopharmaceuticals - AInvest
Ikena Oncology Shareholders Green Light Inmagene Merger: What the 1-for-12 Split Means for Investors - Stock Titan
Why Ikena Oncology Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
What makes Ikena Oncology Inc. stock price move sharplySafe High Return Entry Points - Newser
SBET spends $25.7M on 10,000 ETH; Share-reserve waiver opens ATM issuances | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology Announces Support from ISS and Glass Lewis for Shareholder Vote on Inmagene Merger - Nasdaq
Ikena Oncology Announces ISS and Glass Lewis Recommend - GlobeNewswire
Ikena Oncology (NASDAQ:IKNA) Stock Price Up 1.5% – Here’s Why - Defense World
Ikena Oncology: Inmagene Begins Phase 2b Study for IMG-007 - TipRanks
Two Sigma Investments LP Sells 55,935 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Squarepoint Ops LLC Acquires Shares of 43,640 Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Millennium Management LLC Trims Stake in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Citadel Advisors LLC Lowers Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Two Sigma Advisers LP Has $258,000 Stock Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Bought by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Acquires New Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology Reports Q1 Loss Amid Merger Plans - TipRanks
Ikena Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Ikena Oncology, Inc. SEC 10-Q Report - TradingView
Renaissance Technologies LLC Sells 70,400 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Purchases 56,936 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Marquis Who's Who Honors Wilmin P. Bartolini for Expertise in Pharmaceutical Consulting - 24-7 Press Release Newswire
Prudential Financial Inc. Trims Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology stock hits 52-week low at $0.98 amid market challenges - Investing.com Canada
Ikena Oncology stock hits 52-week low at $0.98 amid market challenges By Investing.com - Investing.com South Africa
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges - Investing.com Australia
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges By Investing.com - Investing.com South Africa
Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Business Wire
Ikena Oncology: Investor Caution as Dividend Payments Remain Unlikely - TipRanks
Ikena Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ikena Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Ikena Oncology, Inc. SEC 10-K Report - TradingView
Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Decreases By 11.8% - MarketBeat
Discovering February 2025's Promising Penny Stocks On US Exchanges - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Stock Price Down 0.7%Here's Why - MarketBeat
A History of Outperforming Analyst Forecasts and Beating the Odds: Ikena Oncology Inc (IKNA) - SETE News
Understanding the Risks of Investing in Ikena Oncology Inc (IKNA) - Knox Daily
Ikena Oncology Merger with Inmagene Biopharmaceuticals and Private Placement Financing - Leerink Partners
Ikena Oncology Inc (IKNA) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.10%
大文字化:
|
ボリューム (24 時間):